|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
FGF19 is overexpressed in a significant proportion of human hepatocellular carcinomas (HCC), and activation of its receptor FGFR4 promotes HCC cell growth.
|
25346390 |
2015 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.
|
25822088 |
2015 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification.
|
24798001 |
2014 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this study, we describe an engineered FGF19 (M70) that fully retains bile acid regulatory activity but does not promote HCC formation, demonstrating that regulating bile acid metabolism is distinct and separable from tumor-promoting activity.
|
24728076 |
2014 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
High-throughput short-read sequencing of exomes and whole cancer genomes in multiple human hepatocellular carcinoma (HCC) cohorts confirmed previously identified frequently mutated somatic genes, such as TP53, CTNNB1 and AXIN1, and identified several novel genes with moderate mutation frequencies, including ARID1A, ARID2, MLL, MLL2, MLL3, MLL4, IRF2, ATM, CDKN2A, FGF19, PIK3CA, RPS6KA3, JAK1, KEAP1, NFE2L2, C16orf62, LEPR, RAC2, and IL6ST.
|
24379610 |
2013 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, we found that the FGF19 recombinant protein could increase the proliferation (P < 0.01, n = 12) and invasion (P < 0.01, n = 6) capabilities of human hepatocellular carcinoma cell lines and inhibited their apoptosis (P < 0.01, n = 12).
|
22309595 |
2012 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Finally, we demonstrate a positive correlation between FGF19 and AR expression in human HCC tissues, therefore supporting in clinical samples our experimental observations.
|
23285165 |
2012 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although it is widely assumed that CCND1 is the main driving oncogene of this common amplicon (15% frequency in HCC), both forward-transformation assays and RNAi-mediated inhibition in human HCC cells established that FGF19 is an equally important driver gene in HCC.
|
21397858 |
2011 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data suggest that activation of FGFR4 is the mechanism whereby FGF19 can increase hepatocyte proliferation and induce hepatocellular carcinoma formation.
|
20018895 |
2010 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This antibody abolished FGF19-mediated activity in vitro and inhibited growth of colon tumor xenografts in vivo and effectively prevented hepatocellular carcinomas in FGF19 transgenic mice.
|
17599042 |
2008 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings suggest a previously unknown role for FGF19 in hepatocellular carcinomas.
|
12057932 |
2002 |
|
Metabolic Syndrome X
|
0.220 |
Biomarker
|
disease |
BEFREE |
This view is consistent with known physiological role of ACOX1 in yielding precursors of specialized proresolving mediators (SPM) and with characteristics of aging and related disorders including reduced PGC1-<i>α</i> function and improvement by strategies rising ACOX1 (via hormonal gut FGF19 and nordihydroguaiaretic acid in metabolic syndrome and diabetes conditions) and SPM (neurodegenerative disorders, atherosclerosis, and stroke).
|
29765501 |
2018 |
|
Liver Cirrhosis
|
0.220 |
Biomarker
|
disease |
CTD_mouse |
The effect of fibroblast growth factor 15 deficiency on the development of high fat diet induced non-alcoholic steatohepatitis.
|
28673684 |
2017 |
|
Liver Cirrhosis
|
0.220 |
Biomarker
|
disease |
BEFREE |
The independent determinants of FGF-19 concentrations were found to be the stage (severity) of liver cirrhosis (p=0.04) and INR (p=0.03).
|
28954507 |
2017 |
|
Metabolic Syndrome X
|
0.220 |
Biomarker
|
disease |
BEFREE |
FGF19 is a promising therapeutic target for the metabolic syndrome and cholestatic diseases, but enthusiasm for its use has been tempered by FGF19-mediated induction of proliferation and hepatocellular carcinoma.
|
28178326 |
2017 |
|
Metabolic Syndrome X
|
0.220 |
Biomarker
|
disease |
CTD_mouse |
The effect of fibroblast growth factor 15 deficiency on the development of high fat diet induced non-alcoholic steatohepatitis.
|
28673684 |
2017 |
|
Liver Cirrhosis
|
0.220 |
Biomarker
|
disease |
BEFREE |
Further study is required to investigate the potential role of FGF19 amplification in driving hepatocarcinogenesis in patients with liver cirrhosis and to investigate the potential of anti-FGF19 treatment in these patients.
|
24798001 |
2014 |
|
Fibrosis, Liver
|
0.210 |
Biomarker
|
disease |
BEFREE |
In this study, complimentary in vivo and in vitro approaches were used: (1) CCl<sub>4</sub> -induced LF model in wild type (WT), Fgf15<sup>-/-</sup> , and Fgf15 transgenic (TG) mice with BA levels modulated by feeding cholestyramine- or cholic acid-containing diets; (2) analysis of primary HSCs isolated from WT and Fgf15<sup>-/-</sup> mice; and (3) treatment of a human HSC line, LX-2, with FXR activators and/or recombinant FGF19 protein.
|
31206730 |
2020 |
|
Fibrosis, Liver
|
0.210 |
Biomarker
|
disease |
CTD_mouse |
The effect of fibroblast growth factor 15 deficiency on the development of high fat diet induced non-alcoholic steatohepatitis.
|
28673684 |
2017 |
|
Acute alcoholic liver disease
|
0.200 |
Therapeutic
|
disease |
RGD |
Dihydroartemisinin protects against alcoholic liver injury through alleviating hepatocyte steatosis in a farnesoid X receptor-dependent manner.
|
27939985 |
2017 |
|
Insulin Resistance
|
0.200 |
Biomarker
|
phenotype |
CTD_mouse |
The effect of fibroblast growth factor 15 deficiency on the development of high fat diet induced non-alcoholic steatohepatitis.
|
28673684 |
2017 |
|
Insulin Sensitivity
|
0.200 |
Biomarker
|
phenotype |
CTD_mouse |
The effect of fibroblast growth factor 15 deficiency on the development of high fat diet induced non-alcoholic steatohepatitis.
|
28673684 |
2017 |
|
Hepatic Insufficiency
|
0.200 |
Biomarker
|
phenotype |
CTD_mouse |
The effect of fibroblast growth factor 15 deficiency on the development of high fat diet induced non-alcoholic steatohepatitis.
|
28673684 |
2017 |
|
Colitis
|
0.200 |
Biomarker
|
disease |
CTD_mouse |
Alterations in Enterohepatic Fgf15 Signaling and Changes in Bile Acid Composition Depend on Localization of Murine Intestinal Inflammation.
|
27580383 |
2016 |
|
Necrosis
|
0.200 |
Biomarker
|
phenotype |
CTD_mouse |
Fibroblast growth factor 15 deficiency impairs liver regeneration in mice.
|
24699334 |
2014 |